Biogen said it completed the Apellis acquisition on May 14, 2026, paying shareholders $41.00 in cash per share (about $5.3 billion) and granting one contingent value right of up to $4.00 per share. It said it funded the deal with $2.0 billion and the 2026 Term Loan, among other sources.

1. 01

   Biogen said it completed the Apellis acquisition on May 14, 2026, paying shareholders $41.00 in cash per share (about $5.3 billion) and granting one contingent value right of up to $4.00 per share. It said it funded the deal with $2.0 billion and the 2026 Term Loan, among other sources.

2. 02

   The company said SYFOVRE U.S. sales were $191.3 million and EMPAVELI sales were $51.5 million in Q3 2026. It said both products were added through the Apellis acquisition in May 2026.

3. 03

   Biogen said it completed the RayThera acquisition on August 6, 2026 and made an upfront payment of $225.0 million. It said acquired in-process research and development, upfront and milestone expense was $283.8 million in Q3.

4. 04

   Biogen said cash, cash equivalents and marketable securities fell to about $1.3 billion as of September 30, 2026 from about $4.2 billion as of December 31, 2025. The company cited net cash paid for the Apellis acquisition, $5.1 billion, as the main factor.

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.